ReviewJournal of clinical hypertension (Greenwich, Conn.)2006
Angiotensin receptor blockers: new considerations in their mechanism of action.
Review in Journal of clinical hypertension (Greenwich, Conn.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06539234 (Angiotensin II Stress Test. Renin Kinetics During Treatment of Vasoplegic Shock With Angiotensin II in Relation to Hemodynamic Response to Treatment With Angiotensin II.), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Angiotensin II Stress Test. Renin Kinetics During Treatment of Vasoplegic Shock With Angiotensin II in Relation to Hemodynamic Response to Treatment With Angiotensin II.
Who cites it
6 citing papers in PubMed.
- Imidazole-Based ATMolecules (Basel, Switzerland) · 2026Article
- Angiotensin II-Real-Life Use and Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
- The Renin Angiotensin System as a Therapeutic Target in Traumatic Brain Injury.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Review
- Losartan-Induced Angioedema: A Case Report.Cureus · 2023Article
- AT1 receptor blockade attenuates insulin resistance and myocardial remodeling in rats with diet-induced obesity.PloS one · 2014Article
- Beneficial effects of angiotensin II type 1 receptor blocker antihypertensive treatment on inflammation indices: the effect of smoking.Journal of clinical hypertension (Greenwich, Conn.) · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiotensin receptor blockers are one of several drug classes that act by hindering activity of the renin-angiotensin axis. Angiotensin receptor blockers act by selectively blocking the binding of angiotensin II to the angiotensin type 1 receptor but not the angiotensin type 2 receptor. Compounds in this class are as effective as most other antihypertensive drug classes in reducing blood pressure in the patient with hypertension. The mechanism of action of an angiotensin receptor blocker, which seemed a straightforward proposition early on, has of late become more convoluted with a host of class and compound-specific concerns having emerged. As the mechanistic basis for the action(s) of angiotensin receptor blockers more completely unfolds, added credence may ultimately be lent to widely touted and often overstated intraclass differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.